5 Analysts Have This To Say About Lexicon Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past three months, 5 analysts have evaluated Lexicon Pharmaceuticals (NASDAQ:LXRX), with all ratings being bullish. The average 12-month price target remains at $10.00. Key analyst Joseph Pantginis from HC Wainwright & Co. consistently maintains a 'Buy' rating with a $10.00 price target. Lexicon Pharmaceuticals has shown significant revenue growth and maintains a prudent debt management strategy.
August 02, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals (NASDAQ:LXRX) has received 5 bullish ratings from analysts over the past three months, with a consistent 12-month price target of $10.00. The company has shown significant revenue growth and maintains a prudent debt management strategy.
All 5 analysts have given bullish ratings, indicating strong positive sentiment. The consistent price target of $10.00 suggests stable expectations. Significant revenue growth and prudent debt management further support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100